{
    "body": "Against which organisms has reverse vaccinology been used?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23527566", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22261504", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16107075", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23514126", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17291333", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16848907", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22521592", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20127115", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21993656", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20671958", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23533646", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22434357", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12531326", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11257410", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19179021"
    ], 
    "ideal_answer": [
        "Reverse Vaccinology (RV) was first applied to serogroup B Neisseria meningitidis. This work induced further research of other pathogens in the same way: Porphyromonas gingivalis, Streptococcus pneumoniae, Chlamydia pneumoniae, Bacillus anthracis, group B streptococci, Helicobacter pylori and Mycobacterium tuberculosis. Concerning animal-affecting organisms, RV has been applied for vaccine design against Theileria parva, Brachyspira hyodysenteriae,  Echinococcus granulosus, Ehrlichia ruminantium, Leishmania spp, Rhipicephalus microplus and Brucella melitensis."
    ], 
    "exact_answer": [
        [
            "Neisseria meningitidis (serogroup B)"
        ], 
        [
            "Porphyromonas gingivalis"
        ], 
        [
            "Streptococcus pneumoniae"
        ], 
        [
            "Chlamydia pneumoniae"
        ], 
        [
            "Bacillus anthracis"
        ], 
        [
            "group B streptococci"
        ], 
        [
            "Helicobacter pylori"
        ], 
        [
            "Mycobacterium tuberculosis"
        ], 
        [
            "Theileria parva"
        ], 
        [
            "Brachyspira hyodysenteriae"
        ], 
        [
            "Echinococcus granulosus"
        ], 
        [
            "Ehrlichia ruminantium"
        ], 
        [
            "Leishmania spp"
        ], 
        [
            "Rhipicephalus microplus"
        ], 
        [
            "Brucella melitensis"
        ]
    ], 
    "type": "list", 
    "id": "51601071298dcd4e51000038", 
    "snippets": [
        {
            "offsetInBeginSection": 762, 
            "offsetInEndSection": 912, 
            "text": "The potential of this new approach is illustrated by the use of reverse vaccinology for the development of a vaccine against serogroup B meningococcus", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/11257410", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 858, 
            "offsetInEndSection": 946, 
            "text": "The Neisseria meningitidis serogroup B project, the first example of Reverse Vaccinology", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/12531326", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 71, 
            "text": "Reverse vaccinology and vaccines for serogroup B Neisseria meningitidis", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16107075", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 434, 
            "offsetInEndSection": 539, 
            "text": "This process, first applied to serogroup B Neisseria meningitidis, has been termed as reverse vaccinology", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16107075", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 69, 
            "text": "A reverse vaccinology approach to swine dysentery vaccine development", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19179021", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 175, 
            "text": "Swine dysentery (SD) is a mucohaemorrhagic colitis of pigs resulting from infection of the large intestine with the anaerobic intestinal spirochaete Brachyspira hyodysenteriae", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19179021", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 121, 
            "text": "Reverse vaccinology approach identify an Echinococcus granulosus tegumental membrane protein enolase as vaccine candidate", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20127115", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 2039, 
            "offsetInEndSection": 2148, 
            "text": "Reverse vaccinology process identified E. granulosus tegumental membrane protein enolase as vaccine candidate", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20127115", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 868, 
            "offsetInEndSection": 979, 
            "text": "The application of RV to Neisseria meningitidis serogroup B represents the first success of this novel approach", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21993656", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 125, 
            "text": "Identification of Ehrlichia ruminantium proteins that activate cellular immune responses using a reverse vaccinology strategy", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22261504", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 166, 
            "text": "Ehrlichia ruminantium is an obligate intracellular bacterial pathogen which causes heartwater, a serious tick-borne disease of ruminants throughout sub-Saharan Africa", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22261504", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 105, 
            "text": "A reverse vaccinology approach for the identification of potential vaccine candidates from Leishmania spp", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22434357", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 155, 
            "text": "A systematic, functional genomics, and reverse vaccinology approach to the identification of vaccine candidates in the cattle tick, Rhipicephalus microplus", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22521592", 
            "endSection": "title"
        }
    ]
}